Collegium Pharmaceutical Inc (COLL) - Total Assets
Based on the latest financial reports, Collegium Pharmaceutical Inc (COLL) holds total assets worth $1.61 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See COLL book value for net asset value and shareholders' equity analysis.
Collegium Pharmaceutical Inc - Total Assets Trend (2013–2024)
This chart illustrates how Collegium Pharmaceutical Inc's total assets have evolved over time, based on quarterly financial data.
Collegium Pharmaceutical Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Collegium Pharmaceutical Inc's total assets of $1.61 Billion consist of 29.0% current assets and 71.0% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 4.2% |
| Accounts Receivable | $228.54 Million | 13.7% |
| Inventory | $35.56 Million | 2.1% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $891.40 Million | 53.6% |
| Goodwill | $162.33 Million | 9.8% |
Asset Composition Trend (2013–2024)
This chart illustrates how Collegium Pharmaceutical Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Collegium Pharmaceutical Inc (COLL) total market value.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Collegium Pharmaceutical Inc's current assets represent 29.0% of total assets in 2024, a decrease from 91.4% in 2013.
- Cash Position: Cash and equivalents constituted 4.2% of total assets in 2024, down from 83.6% in 2013.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 62.0% of total assets, an increase from 0.0% in 2013.
- Asset Diversification: The largest asset category is intangible assets at 53.6% of total assets.
Collegium Pharmaceutical Inc Competitors by Total Assets
Key competitors of Collegium Pharmaceutical Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Takeda Pharmaceutical Co Ltd ADR
NYSE:TAK
|
USA | $15.42 Trillion |
|
Regencell Bioscience Holdings Ltd
NASDAQ:RGC
|
USA | $5.76 Million |
|
Changchun High & New Technology Industries Group Inc
SHE:000661
|
China | CN¥31.46 Billion |
|
Yuhan Corp.
KO:000100
|
Korea | ₩3.05 Trillion |
|
Tonghua Dongbao Pharmaceutical Co Ltd
SHG:600867
|
China | CN¥8.15 Billion |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858
|
China | CN¥19.57 Billion |
|
Guangdong Zhongsheng Pharmaceutical Co Ltd
SHE:002317
|
China | CN¥5.17 Billion |
|
Guobang Pharma Ltd
SHG:605507
|
China | CN¥10.58 Billion |
Collegium Pharmaceutical Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.36 | 0.97 | 1.16 |
| Quick Ratio | 1.27 | 0.88 | 1.10 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $160.94 Million | $-15.62 Million | $38.44 Million |
Collegium Pharmaceutical Inc - Advanced Valuation Insights
This section examines the relationship between Collegium Pharmaceutical Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 5.19 |
| Latest Market Cap to Assets Ratio | 0.65 |
| Asset Growth Rate (YoY) | 45.5% |
| Total Assets | $1.66 Billion |
| Market Capitalization | $1.08 Billion USD |
Valuation Analysis
Below Book Valuation: The market values Collegium Pharmaceutical Inc's assets below their book value (0.65x), which may indicate investor concerns about asset quality or future growth.
Rapid Asset Growth: Collegium Pharmaceutical Inc's assets grew by 45.5% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Collegium Pharmaceutical Inc (2013–2024)
The table below shows the annual total assets of Collegium Pharmaceutical Inc from 2013 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.66 Billion | +45.51% |
| 2023-12-31 | $1.14 Billion | -2.63% |
| 2022-12-31 | $1.17 Billion | +69.65% |
| 2021-12-31 | $692.08 Million | +7.49% |
| 2020-12-31 | $643.84 Million | +110.20% |
| 2019-12-31 | $306.30 Million | +5.17% |
| 2018-12-31 | $291.25 Million | +114.83% |
| 2017-12-31 | $135.57 Million | -16.32% |
| 2016-12-31 | $162.02 Million | +65.80% |
| 2015-12-31 | $97.72 Million | +1819.80% |
| 2014-12-31 | $5.09 Million | -43.66% |
| 2013-12-31 | $9.03 Million | -- |
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more